Status:

UNKNOWN

Outcome of Patients With Primary Aldosteronism

Lead Sponsor:

Changi General Hospital

Collaborating Sponsors:

Singapore General Hospital

Conditions:

Primary Aldosteronism

Primary Aldosteronism Due to Aldosterone Producing Adenoma

Eligibility:

All Genders

14-100 years

Brief Summary

Majority of patients with hypertension have primary hypertension (without an underlying cause). Primary aldosteronism (PA) is the most common cause of secondary hypertension, and can be found in 5-10%...

Eligibility Criteria

Inclusion

  • Patients with suspected primary aldosteronism

Exclusion

  • Nil

Key Trial Info

Start Date :

October 1 2016

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

July 30 2022

Estimated Enrollment :

600 Patients enrolled

Trial Details

Trial ID

NCT04428827

Start Date

October 1 2016

End Date

July 30 2022

Last Update

August 12 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Changi General Hospital

Singapore, Singapore, 529889